Who are Recombinant human Growth Hormone's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Change in daily dosage of Growth Hormone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/recombinant-human-growth-hormone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Recombinant human Growth Hormone — Competitive Intelligence Brief

Recombinant human Growth Hormone (Recombinant human Growth Hormone) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Growth hormone replacement therapy. Area: Endocrinology.

marketed Growth hormone replacement therapy Growth hormone receptor (GHR) Endocrinology Small molecule Live · refreshed every 30 min

Target snapshot

Recombinant human Growth Hormone (Recombinant human Growth Hormone) — University of Pennsylvania. Recombinant human growth hormone binds to growth hormone receptors on target cells to stimulate growth, metabolism, and protein synthesis.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Recombinant human Growth Hormone TARGET	Recombinant human Growth Hormone	University of Pennsylvania	marketed	Growth hormone replacement therapy	Growth hormone receptor (GHR)
Change in daily dosage of Growth Hormone	Change in daily dosage of Growth Hormone	Amsterdam UMC, location VUmc	marketed	Growth hormone replacement therapy	Growth hormone receptor (GHR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Growth hormone replacement therapy class)

Amsterdam UMC, location VUmc · 1 drug in this class
University of Pennsylvania · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Recombinant human Growth Hormone — Competitive Intelligence Brief. https://druglandscape.com/ci/recombinant-human-growth-hormone. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab